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ABSTRACT
Background: CD73 is an ectoenzyme involved in the production of adenosine. 
It exerts immunosuppressive and protumoral roles and has emerged as a potential 
immuno-oncology target.
Results: CD73 expression was detected in TC in 54% of melanoma metastases, 
involving < 50% TC in the majority of the cases, with variable intensity. CD73 
expression was significantly associated with a lower Breslow’s depth of the primary 
lesion and was more frequent in patients having received prior non-surgical therapies. 
In an adjusted analysis, CD73 expression in TC (H-score > 37.5 or intensity > 1) 
significantly correlated to decreased overall survival (OS) from biopsy. Of the 
samples containing TIMC, 35% presented CD73+ TIMC. Highly infiltrated tumors 
were more likely to contain CD73+ TIMC. CD73 expression in TIMC (percentage ≥1%) 
significantly correlated with improved OS from biopsy.
Conclusions: Immunohistochemistry detected CD73 expression in more than half 
of metastatic melanomas. While CD73 expression in TC significantly correlated with 
decreased OS, CD73 expression in TIMC significantly associated with improved OS. 
These results encourage the study of anti-CD73 therapies for metastatic melanoma 
patients. 
Methods: CD73 expression was assessed by immunohistochemistry in metastatic 
melanomas from 114 patients. Immunostainings were evaluated in tumor cells (TC) 
(percentage, intensity (1–3) and H-score) and in tumor-infiltrating mononuclear cells 
(TIMC) (percentage).
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INTRODUCTION
CD73 is an ectoenzyme with a 5′-nucleotidase 
activity, which catalyzes the rate-limiting step in the 
generation of extracellular adenosine [1–3]. In addition, 
CD73 has an adhesion role participating in cell-cell and 
cell-matrix interactions [1, 4–6]. Structurally, CD73 
consists of two identical 70-kD subunits, each with an 
N-terminal domain (containing binding sites for catalytic 
ions) and a C-terminal domain (containing an AMP 
binding site), anchored to the plasma membrane [1]. In 
physiological conditions, CD73 is expressed by stromal 
cells, follicular dendritic cells, and endothelial cells [1] but 
also by variable proportions of adaptive immune cells (B 
cells and some T-cell subsets) [7, 8]. CD73 expression and 
function is increased by hypoxic conditions and several 
inflammatory mediators [1].
CD73 participates in the catabolism of extracellular 
ATP which is first converted by the ectoenzyme CD39 to 
ADP and AMP, the latter being transformed to adenosine 
by CD73 [3]. In conditions of ischemia, hypoxia or 
inflammation, extracellular adenosine levels increase 
[1]. In these circumstances, adenosine down-regulates 
inflammatory and immune responses, modulating the 
amplitude of physiological responses and preventing 
collateral tissue damage [3]. Adenosine promotes 
regulatory T cell function, decreases T helper 1 and natural 
killer cell activity, inhibits M1 macrophage activation, 
promotes macrophage M2 differentiation and drives 
dendritic cells towards an anti-inflammatory cytokine 
profile [3, 9]. The four transmembrane adenosine receptors 
(A
1
, A
2a
, A
2b
 and A3) are expressed by immune (mostly A2a, 
A
2b
) and endothelial cells [3].
Adenosine stimulates the production of vascular 
endothelial growth factor by endothelial cells and 
macrophages, inducing angiogenesis [3]. When expressed 
by vascular endothelial cells, CD73 produces adenosine, 
which, by a paracrine effect, inhibits vascular permeability 
and lymphocyte trafficking [10]. Conversely, CD73 
engagement on human peripheral blood lymphocytes 
increases their binding to endothelial cells by increasing 
LFA-1 avidity in a non-enzymatic way [6].
The adenosine cycle can be viewed as a metabolic 
immune checkpoint, and strategies to interfere with this 
cascade seem promising [1]. 
Several immunohistochemistry (IHC)-based 
studies of human samples have been recently published. 
In colorectal cancer, higher tumoral CD73 and lower 
stromal CD73 expression significantly associated with 
higher TNM stage, presence of lymphatic metastasis 
and poor tumor differentiation. Expression in tumor 
cells also associated with a higher risk of death [11]. 
CD73 expression on tumor cells of triple negative breast 
cancer was significantly associated with reduced overall 
survival and negatively correlated with tumor immune 
infiltration [12]. In primary head and neck squamous 
cell carcinomas and corresponding metastatic lymph 
nodes, CD73 expression correlated positively with tumor 
stage and associated with reduced overall survival [13]. 
Papillary thyroid and pancreatic ductal carcinomas present 
higher CD73 expression compared with normal thyroid or 
pancreas tissue, respectively [14, 15].
In ovarian carcinoma, CD73 overexpression 
associated with better 5-year overall survival. This may be 
due to that overexpression of CD73 was more frequently 
observed in mucinous and clear cell adenocarcinomas 
compared to serous or endometrioid adenocarcinomas 
and in patients with known good prognostic factors. 
The CD73-negative group presented significantly more 
infiltration of regulatory T cells [16].
Regarding melanoma, one recent study showed that 
cell lines derived from metastatic melanomas express 
more CD73 than those derived from normal melanocytes 
or primary melanomas [5]. Primary melanomas that 
do not epigenetically downregulate the transcription 
of the NT5E gene (that encodes CD73) were found to 
metastasize more often [17]. Studying melanoma cells 
in CD73-deficient mice, CD73 was shown to promote 
MAP-kinase signaling, tumor growth and angiogenesis 
[18]. The same study reported tumor cell-associated CD73 
contribution to metastasis formation through attachment 
to endothelium [18]. In addition, the CD73-tenascin-C 
complex was shown to be involved in cell migration 
and invasion in melanoma cell lines [4, 5]. In a mouse 
model of melanoma, the use of a specific CD73 inhibitor 
improved T- and B-cell-mediated anti-tumor immunity 
and reduced tumor growth [19].
In this context, our study aims at characterizing 
CD73 expression in human metastatic melanoma, its 
association with clinicopathological parameters and its 
prognostic impact.
RESULTS
Clinicopathological features
The demographics and clinicopathological features 
are summarized in Table 1. Patients comprised 55 men 
and 59 women with a median age of 67 years at the time 
the examined metastatic biopsy was excised (range 23–
91 years). The corresponding primary melanomas were 
cutaneous in the majority of cases (79%) while ocular, 
mucosal and unknown primary site melanomas accounted 
for 21% of the cases. Cutaneous melanomas included 33 
nodular melanomas, 30 superficial spreading melanomas, 
9 acral lentiginous melanomas, 1 lentigo maligna 
melanoma and 17 non-specified cutaneous melanomas.
Examined metastatic sites included lymph nodes 
(40%), skin and subcutaneous tissue (21%) and various 
viscera and central nervous system (39%). Besides 
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Table 1: Clinicopathological features
Clinicopathological features N (%)
Age1 median (range)
Gender
Female
Male
67 years (23–91)
59 (51.8%)
55 (48.3%)
Primary tumor
Melanoma type
Cutaneous 
Ocular 
Mucosal 
Unknown primary site
Initial T
T1-2
T3-4
Breslow’s depth2 mean (±sd)
Initial N
N0
N1-3
Initial M
M0
M1
Mutation status
BRAF mutated
NRAS mutated
cKIT mutated
90 (79.0%)
11 (9.7%)
1 (0.9%)
12 (10.5%)
32/96 (33.3%)
64/96 (66.7%)
4.2 mm (±5.9)
38/91 (41.8%)
53/91 (58.2%)
82/98 (83.7%)
16/98 (16.3%)
41/77 (53.6%)
13/35 (37.1%)
1/19 (5.3%)
Metastatic lesion
Clinical stage1
Stage III
Stage IV
Biopsy sites
Lymph node
Skin and subcutaneous tissue
Lung
Central Nervous System (CNS)
Liver
Gastrointestinal tract
Other (bone, breast, peritoneum, thyroid and spleen)
Previous treatments
Treatment naïve
Previously treated
Treatments received
Radiation therapy
Chemotherapy
Targeted therapy
Immunotherapy
41 (36.0%)
73 (64.0%)
46 (40.4%)
24 (21.1%)
18 (15.8%)
9 (7.9%)
8 (7.0%)
4 (3.5%)
5 (4.4%)
73/113 (64.6%)
40/113 (35.4%)
27/40 (67.5%)
12/40 (30.0%)
11/40 (27.5%)
21/40 (52.5%)
Follow-up Mean (±sd)
Time from diagnosis to biopsy
Time from diagnosis to death/latest news
Time from biopsy to death/latest news
Deaths from any cause N (%)
48.1 months (±60.6)
66.3 months (±63.6)
17.6 months (±16.3)
40 (35.1%)
1. At the time of sample collection. 2. Percentage based on the total number of patients with known Breslow’s depth 
(N = 90). The 24 other patients had ocular, mucosal or unknown primary site melanoma.
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surgery, 73 patients were treatment-naïve and 40 patients 
had received radiotherapy, chemotherapy, immunotherapy 
and/or targeted therapy. Of these, 10 patients had been 
treated by radiotherapy only. Twenty-one patients had 
received immunotherapy treatments including: immune 
checkpoint inhibitors (12 patients, of which 8 received 
anti-CTLA4 mAb, one received anti-PD1 mAb and 3 
received both), cancer vaccines (3 patients), IFN-alpha (3 
patients), cancer vaccines and IFN-alpha (1 patient) and 
anti-LAG-3 mAb (2 patients).
Metastatic melanoma cells frequently express 
CD73 
All lesions examined presented some expression 
of CD73 in endothelial or stromal cells which accounted 
for positive internal controls. Sixty-two samples (54%) 
contained CD73 positive tumor cells (TC) (Figure 1). 
Of these, 21 samples presented CD73 in less than 5% 
of TC, 21 in 5–50% of TC and 20 in 50–100% of TC 
(Supplementary Table 1). In seventeen metastases, TCs 
expressed CD73 with an intensity of 1, 27 with an intensity 
of 1.5–2 and 18 with an intensity of 2.5–3. H-scores varied 
from 0 to 285. Two thirds (39/62) stained with a membrane 
pattern, while 12 presented a cytoplasmic pattern and 11 
presented both (Figure 2).
The association between CD73 expression in the 
metastases, the pathological features of the primary tumor 
and the clinical parameters was assessed by univariable 
multinomial regression analysis (Table 2). Age and gender 
did not significantly influence the H-score. Primary 
melanoma type and mutational status did not show any 
association with CD73 expression in metastatic lesions. 
Cases presenting deeper invasion (Breslow’s depth) in the 
primary lesion presented significantly less CD73 in their 
metastases (P = 0.01). Patients with advanced pathologic 
stage (M1 and N1-3) at the time of the primary diagnosis 
tended to have more CD73 expression in their metastases. 
With respect to clinical stage at the time the metastasis was 
examined, lesions from patients at clinical stage IV tended 
to express more CD73 than those at clinical stage III.
Patients that received non-surgical treatment prior 
to sample collection had higher levels of CD73 in the 
metastases analyzed (P = 0.003). Only 14 of 73 treatment-
naïve patients (19%) expressed CD73 with an H-score 
> 37.5. Conversely, 13 of 40 patients (33%) having 
previously received a non-surgical treatment (radiotherapy, 
chemotherapy, targeted therapy and/or immunotherapy) 
had a CD73 H-score > 37.5. More specifically, 33% (9/27) 
of patients treated with radiotherapy, 33% (4/12) of patients 
treated with chemotherapy, 36% (4/11) of patients treated 
with targeted therapy and 33% (7/21) of patients treated 
with immunotherapy (including 5/12, 42%, treated with 
immune checkpoint inhibitors) had a CD73 H-score > 37.5. 
Of the 8 patients who received an anti-CTLA4 monoclonal 
antibody (mAb), 6/8 presented some CD73 staining in TC 
(4/8 in > 25% of TC, 3/8 with an H-score > 37.5). Two 
of the 3 patients who received anti-CTLA4 plus anti-PD1 
mAbs expressed CD73 in > 25% of TC (H-score > 37.5) 
and one was CD73-negative. The patient who received only 
an anti-PD1 mAb presented ≤5% of TC staining.
Expression of CD73 in tumor infiltrating 
mononuclear cells (TIMC) correlates with a 
higher TIMC content
Most samples (93%) contained TIMC, mostly in 
low quantity (Table 3). Of these, 35% contained TIMC 
with some expression of CD73 (68% in ≤5% of TIMC and 
32% in 5–50% of TIMC) (Figure 3, Table 3). Interestingly, 
specimens with more abundant TIMC were more likely 
to show CD73-positive TIMC (P < 0.001, Table 4). No 
Figure 1: Distribution of CD73 staining in tumor cells. Distribution of CD73 staining in the tumor cells of the 114 melanoma 
metastases according to percentage of TC staining (0 to >90%), intensity of staining (0 to 3) and H-score (0 to >37.5). 
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correlation was found between CD73 expression in TIMC 
and in TC (Table 2).
CD73 expression in metastatic melanoma cells 
correlates with poor clinical outcome
The average follow-up (from biopsy to date of death 
or latest news) was 17.75 months and 50% of the patients 
were followed for more than one year. By the end of the 
follow-up period, 40 patients had deceased from any cause 
(Table 1). Survival curves by initial T, N and M stage were 
as expected (Supplementary Figure 1) [20].
To characterize the prognostic significance of CD73 
expression, overall survival (OS) from biopsy was studied 
(Supplementary Table 2). In a multivariable analysis, 
initial T stage and previous treatments were found to be 
associated to the H-score at level of 20% (P-value < 0.20) 
(Supplementary Table 3). As clinical stages III and IV have 
very different prognosis, this variable was used to adjust 
OS from biopsy, together with initial T stage and previous 
treatments [20]. When adjusting to these variables, higher 
levels of CD73 expression in TC correlated with decreased 
OS from biopsy: a) H-score > 37.5 vs. H-score 0: Hazard 
ratio (HR) 2.37, P = 0.04; b) %TC > 25% vs. %TC 0–25%: 
HR 1.51, P = 0.28; c) intensity > 1 vs. intensity ≤1: HR 2.70; 
P = 0.005) (Figure 4). Concordantly, CD73 expression 
in TC also correlated with decreased OS from diagnosis 
(Figure 4).
Regarding TIMC quantity, the presence of TIMC 
(1–3 vs. 0) associated with improved OS from diagnosis 
(Table 3). In a non-adjusted analysis, CD73 expression in 
TIMC (1–50% vs. 0%) significantly improved OS from 
biopsy (HR = 0.43, P = 0.044) (Table 3).
CD73 expression features temporal and spatial 
heterogeneity
Multiple metastatic lesions in 16 patients 
were analyzed to gain insight into CD73 expression 
heterogeneity (Supplementary Table 4). Sequential 
biopsies of the same lesion at ≥2 months interval showed 
either stability (three cases fully concordant and one 
case differing by <5%) or an increase (three cases) in the 
percentage of TC staining over time. Metastatic lesions 
Figure 2: Metastatic melanoma lesions presenting CD73 staining in tumor cells. (A) Melanoma metastasis presenting 5–25% 
of tumor cells (TC) staining (arrows), with an intensity of 1 and a cytoplasmic pattern. (B) Metastatic melanoma with ≤5% of TC staining, 
with moderate to strong intensity (averaged to 2.5) and a membrane pattern (arrows). (C) Metastatic melanoma with 75–90% of TC 
staining, intensity 2 to 3, mixed pattern (membrane and cytoplasmic staining). Surrounding stromal tissue is mostly unstained (*). (D) 
Metastatic melanoma with ≥90% of TC homogeneously staining, with strong intensity (3) and a membrane pattern. Surrounding stromal 
tissue is mostly unstained (*). 
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Table 2: CD73 expression in tumor cells by H-score category and association with clinicopathological features
Variable H-score 
0 
N (%)
H-score 
2.5–37.5 
N (%)
H-score > 
37.5–285 
N (%)
2.5–37.5 vs. 0
RRR (P-value)
>37.5–285 vs. 0
RRR (P-value)
Global
P-value
Age1 mean (±sd) 62.8 (±15.3) 63.2 (±14.9) 68.2 (±12.5) 1.00 (0.903) 1.02 (0.118) 0.241
Gender
Male (ref.)
Female
22 (42.3%)
30 (57.7%)
18 (51.4%)
17 (48.6%)
15 (55.6%)
12 (44.4%)
−
0.69 (0.403)
−
0.59 (0.265)
0.482
Melanoma type2
Cutaneous (ref.)
Mucosal
Ocular
Unknown primary site
39 (75.0%)
1 (1.9%)
6 (11.5%)
6 (11.5%)
29 (82.9%)
0
4 (11.4%)
2 (5.7%)
22 (81.5%)
0
1 (3.7%)
4 (14.8%)
−
4.59e–07 (0.993)
0.90 (0.874)
0.45 (0.347)
−
4.67e–07 (0.994)
0.30 (0.273)
1.18 (0.811)
0.578
Initial T stage
T1-2 (ref.)
T3-4
9 (21.4%)
33 (78.6%)
13 (41.9%)
18 (58.1%)
10 (43.5%)
13 (56.5%)
−
0.38 (0.063)
−
0.35 (0.066)
0.086
Breslow’s depth
mean (±sd)
5.7 (±8.4) 2.6 (±1.7) 3.4 (±3.0) 0.77 (0.023) 0.89 (0.201) 0.011
Initial N stage
N0 (ref.)
N1-3
20 (45.5%)
24 (54.6%)
10 (40.0%)
15 (60.0%)
8 (36.4%)
14 (63.6%)
−
1.25 (0.661)
−
1.46 (0.482)
0.762
Initial M stage
M0 (ref.)
M1
40 (85.1%)
7 (14.9%)
22 (84.6%)
4 (15.4%)
20 (80.0%)
5 (20.0%)
−
1.04 (0.955)
−
1.43 (0.581)
0.851
BRAF mutation
No (ref.)
Yes
18 (48.7%)
19 (51.4%)
11 (50.0%)
11 (50.0%)
7 (38.9%)
11 (61.1%)
−
0.95 (0.920)
−
1.49 (0.496)
0.741
NRAS mutation
No (ref.)
Yes
11 (68.8%)
5 (31.3%)
6 (54.6%)
5 (45.5%)
5 (62.5%)
3 (37.5%)
−
1.83 (0.455)
−
1.32 (0.760)
0.755
cKIT mutation
No (ref.)
Yes
10 (90.9%)
1 (9.1%)
4 (100.0%)
0
4 (100.0%)
0
−
2.67e−07 (0.996)
−
2.67e−07 (0.996)
0.567
Clinical stage1
III (ref.)
IV
22 (42.3%)
30 (57.7%)
9 (25.7%)
26 (74.3%)
10 (37.0%)
17 (63.0%)
−
2.12 (0.116)
−
1.25 (0.651)
0.275
Biopsy sites
LN/skin/Sbc (ref.)
Lung
Central nervous system
Other
32 (61.5%)
9 (17.3%)
3 (5.8%)
8 (15.4%)
21 (60.0%)
6 (17.1%)
3 (8.6%)
5 (14.3%)
17 (63.0%)
3 (11.1%)
3 (11.1%)
4 (14.8%)
−
1.02 (0.979)
0.95 (0.939)
1.52 (0.626)
−
0.63 (0.524)
0.94 (0.929)
1.88 (0.467)
0.975
Previous treatments
None (ref.)
CT, RT, TT and/or IT
42 (80.8%)
10 (19.2%)
17 (50.0%)
17 (50.0%)
14 (51.9%)
13 (48.2%)
−
4.2 (0.003)
−
3.9 (0.009)
0.003
TIMC quantity
0 (ref.)
1, 2 or 3
5 (9.6%)
47 (90.4%)
1 (2.9%)
34 (97.1%)
2 (7.4%)
25 (92.6%)
−
3.62 (0.250)
−
1.33 (0.744)
0.434
% of TIMC stained3
0% (ref.)
1–50%4
31 (66.0%)
16 (34.0%)
21 (61.76%)
13 (38.2%)
17 (68.0%)
8 (32.0%)
−
1.20 (0.698)
−
0.91 (0.861)
0.872
Abbreviations: CT: chemotherapy; IT: immunotherapy; LN: lymph node; RRR: relative risk ratio (compared to ref.); RT: 
radiotherapy; Sbc: subcutaneous tissue; TIMC: tumor infiltrating mononuclear cells; TT: targeted therapy.
ref.: variable used as the reference for the statistical analysis.
The P-value was calculated by a univariable multinomial regression analysis. P-values < 0.05 are in bold. 
1. At the time of sample collection. 2. Of the primary melanoma. 3. Of the samples containing TIMC (n = 106). 4. As no 
sample presented more than 50% of TIMC staining, categories above 50% are not represented.
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in different locations biopsied at the same time showed 
approximately the same percentage of TC staining (five 
cases fully concordant and two cases differing by < 25%). 
Finally, different metastatic lesions biopsied at different 
times showed either an increase (three cases), stability 
(two cases differing by < 5%) or a decrease (one case) in 
the percentage of TC staining.
DISCUSSION 
This study shows that all metastatic melanomas 
presented some CD73 expression either by endothelial, 
stromal, tumoral or immune cells. Fifty-four percent 
presented CD73 expression in TC (of those, 52% in > 
25% of TC and 70% with an intensity of 2 or more) and 
approximately a third of the samples containing TIMC had 
CD73-positive TIMC.
We found that CD73 expression in metastatic 
melanomas was significantly associated with a lower 
Breslow’s depth of the primary lesion. Interestingly, a 
recent study analyzed CD73 expression by IHC in human 
primary melanomas (n = 126) and cutaneous metastases (n 
= 70). CD73 expression in primary melanomas (119/126) 
significantly associated with increased tumor thickness, 
ulceration and positive sentinel lymph node, while no 
significant correlation with survival was found. Almost all 
cutaneous melanoma metastasis expressed CD73 (69/70) 
but no correlation was found with age, gender or necrosis 
[21]. The discrepancy between these and our observations 
may be explained by the methodology. In particular, we 
assessed CD73 in metastatic lesions only, and our cohort 
is biased towards a subset of melanoma patients who 
subsequently develop metastatic melanoma, meaning 
that among the cases with lower Breslow’s depth only 
the minority with an unfavorable outcome was selected. 
Consequently, this result should be cautiously interpreted, 
and it is also possible that the biological relevance of 
CD73 expression in melanoma varies according to the 
clinical setting in patients with localized versus metastatic 
disease.
Non-surgical treatments prior to biopsy were also 
significantly associated with a higher CD73 expression 
in TC. Specifically, 42% of patients treated with immune 
checkpoint inhibitors presented an H-score > 37.5 versus 
33% of patients having previously received any non-
surgical treatment. Despite the small numbers (only 12 
patients treated with immune checkpoint inhibitors), 
this observation is consistent with a recent article. 
describing an upregulation of CD73 expression in 
melanoma TC in patients progressing under adoptive T 
cell transfer or immune checkpoint blockade [21]. This 
observation supports the rational for combining current 
immunotherapy strategies with antibody-mediated CD73 
blockade. In this context, evaluating CD73 expression 
before and after current standard immune checkpoint 
treatments would be relevant.
The analysis of multiple metastatic lesions from 
the same patient revealed that CD73 expression is not 
always stable. This analysis seemed to indicate that the 
location of the metastasis does not greatly influence CD73 
expression, whereas time and/or treatment might increase 
its expression. It would be of interest to study paired 
primary and metastatic lesions to clarify the association 
between CD73 expression and the invasive capacity of the 
primary tumor (Breslow’s depth) and to gain insight about 
the dynamics of CD73 expression.
Higher quantities of TIMC infiltrating tumors were 
associated with higher proportions of TIMC expressing 
CD73, however, the evaluation of the proportion of 
immune cells stained was challenging due to the frequent 
colocalization of immune cells with stroma and vessels. 
IHC staining with anti-CD3 and anti-CD20 antibodies 
was performed in three lung metastases. In these 
samples, CD73 staining colocalized with CD20 staining 
(Supplementary Figure 2). Further studies would be useful 
to better characterize the immune cell subtypes expressing 
CD73 in the melanoma milieu.
Figure 3: Melanoma lung metastasis presenting CD73 staining in tumor cells (TC) and in tumor infiltrating 
mononuclear cells (TIMC). (A) low magnification showing positive and negative areas and different intensities of staining; (B) TC 
(arrow heads) present membrane staining (75–90% of TC staining, intensity 2 to 3). A fraction of the TIMC present CD73 staining (arrows).
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Higher levels of CD73 expression in TC were 
significantly associated with decreased OS from biopsy. 
This result supports the notion that CD73 expression in 
TC of metastatic lesions is a factor of poor prognosis for 
melanoma patients. Contrariwise, CD73 expression in 
TIMC was significantly associated with improved OS. 
Notably, higher CD73 expression in TIMC correlated with 
higher TIMC quantity. An explanation for the improved 
OS would be that the well-known benefit of higher 
tumor lymphocytic infiltration might be greater than the 
deleterious effect of increasing CD73 activity in the tumor 
microenvironment. Other two factors worth considering 
would be the participation of CD73 in lymphocyte 
trafficking to the tumor microenvironment [6] and the 
better prognosis associated with B-cell infiltration in 
melanomas (Gourdin N. et al. submitted). Still, this needs 
to be interpreted with caution due to the difficulty in 
assessing the proportion of TIMC staining. This apparent 
double-edged sword character of CD73 expression in the 
tumor microenvironment should be taken into account 
when considering anti-CD73 targeting strategies.
Noteworthy, in mouse models, targeting CD73 
synergized with anti-PD-1 and anti-CTLA4 mAbs, 
suggesting that these might be promising combinations 
[22]. CD73’s potential as a therapeutic target led to a phase 
I trial with an anti-CD73 mAb alone or in combination 
with an anti-PD-L1 mAb (NCT02503774) in advanced 
solid tumors [23].
To our knowledge, this is the first study to 
characterize CD73 expression in human metastatic 
melanomas without restriction to a specific metastatic 
site, also, it is the first to characterize CD73 expression 
in melanoma TIMC. Despite its weaknesses (relatively 
small sample size, only evaluating metastatic lesions 
and a heterogeneous population), this study helps 
to characterize CD73 expression in TC and TIMC, 
bringing insight about the relation of CD73 expression 
with clinicopathological characteristics, treatment and 
prognosis. This study supports CD73 as a frequent 
and influent molecule in metastatic melanoma. Also, 
it encourages the study of anti-CD73 therapies in this 
population.
MATERIALS AND METHODS
Tissue samples and clinical data
Formalin-fixed paraffin-embedded metastatic 
melanoma samples collected between 2005 and 2016 
were retrieved from the archives of the Institute of 
Pathology of the Lausanne University Hospital. Overall, 
713 samples were identified, from 560 patients. Of those, 
114 patients had samples suitable for the purpose of this 
project (surgical specimens or needle biopsies of sufficient 
size and fulfilling ethical requirements). For each patient, 
the first eligible metastatic lesion was selected. Sixteen 
Table 3: Non-adjusted survival analysis of quantity and staining of tumor infiltrating mononuclear cells
Variable
Deceased
N (%)
Alive
N (%)
OS from diagnosis
HR (P-value)
OS from biopsy
HR (P-value)
TIMC quantity
0 (ref.)
1
2
3
4 (10.0%)
21 (52.5%)
11 (27.5%)
4 (10.0%)
4 (5.4%)
37 (50.0%)
24 (32.4%)
9 (12.2%)
(0.271)
− 
0.37
0.33
0.23
(0.428)
− 
0.56
0.39
0.38
TIMC quantity
0 (ref.)
1–3
4 (10.0%)
36 (90.0%)
4 (5.4%)
70 (94.6%)
−
0.34 (0.047)
−
0.48 (0.164)
% of TIMC stained1
0 (ref.)
1–5%
5–25%
25–50%2
29 (80.6%)
5 (13.9%)
2 (5.6%)
0
40 (57.1%)
20 (28.6%)
9 (12.9%)
1 (1.4%)
(0.202)
− 
0.57
0.30
2.70e−14
(0.167)
− 
0.47
0.37
4.72e−16
% of TIMC stained1
0 (ref.)
1–50%2
29 (80.6%)
7 (19.4%)
40 (57.1%)
30 (42.9%)
−
0.46 (0.064)
−
0.43 (0.044)
Abbreviations: HR: Hazard ratio; OS: overall survival; TIMC: tumor infiltrating mononuclear cells.
1. Of the samples containing TIMC (n = 106). 2. As no sample presented more than 50% of TIMC staining, categories 
above 50% are not represented.
ref.: variable used as the reference for the statistical analysis.
The P-value was calculated by a Cox regression model. P-values < 0.05 are in bold.
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patients had more than one eligible lesion, resulting in 25 
extra samples which were examined in a supplementary 
analysis. Clinical and pathological data were obtained 
from medical records.
The study protocol was approved by the cantonal 
ethics committee on human research (Lausanne) (protocol 
17/15). All samples were used in accordance with the 
Declaration of Helsinki.
Immunohistochemistry
IHC was performed using a CD73-specific antibody 
(D7F9A, rabbit monoclonal, #13160, Cell Signaling), 
using the Ventana BenchMark automated stainer. Briefly, 
deparaffinized slides were pre-treated with CC1 for 
60 minutes and incubated with the anti-CD73 primary 
antibody for 60 minutes at 37° C (dilution 1:100). The 
Ultraview DAB detection kit (ref. 760–500) was used, 
followed by hematoxylin counterstaining. An external 
control (reactive tonsil) was stained in each batch 
(Supplementary Figure 3).
An adjacent section was stained with hematoxylin 
and eosin (H&E) (Ventana HE 600 system) for 
morphological reappraisal and to assist IHC interpretation.
IHC slides were scanned using NanoZoomer NDP 
1.0 slide scanner. Leica Biosystems SlidePath software 
(version 4.0.7) was used for visualization and image 
capture.
Figure 4: Adjusted overall survival from biopsy and from diagnosis. OS from biopsy (A–C) and OS from diagnosis (D–F) by 
H-score (reference variable for the statistical analysis (ref.): H-score 0) (A, D); by percentage of TC staining (ref.: TC 0–25%) (B, E); and 
by intensity of staining (ref.: intensity ≤1) (C, F). HR: hazard ratio; OS: overall survival; TC: tumor cells. OS from biopsy is adjusted to 
initial T stage, previous treatments, and clinical stage at the moment of the biopsy (III vs. IV). OS from diagnosis is adjusted to initial T 
stage, previous treatments, and initial M stage.
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Morphological and immunohistochemistry 
analysis
Using the H&E slide, the quantity of TIMC (0: 
none; 1: scarce; 2: moderate; 3: abundant) was reported 
(Supplementary Figure 4).
On IHC stainings, CD73 expression was evaluated 
in TC and TIMC. For TC, the staining pattern (membrane, 
cytoplasmic or both), the percentage expressing CD73 
(percentage groups: 0, ≤5%, 5–25%, 25–50%, 50–75%, 
75–90% or ≥90%) and the intensity of staining (0, 1, 2 
or 3) were reported. When intensity was significantly 
heterogeneous, an average value between the highest and 
lowest intensities observed was taken (1.5, 2 or 2.5). The 
H-score was calculated as percentage (mean value of each 
percentage group) x intensity (H-score: 0–285). For TIMC, 
the percentage staining was assessed (0%, ≤5%, 5–25%, 
25–50%, 50–75% or ≥75%). Staining in endothelium and 
stroma was used as positive internal controls. Evaluation 
of slides was performed independently by a pathology 
resident (IM) and reviewed together with a senior 
pathologist (LdL) to reach a consensus.
Statistical analysis
Statistical analysis was performed using Stata 14 
software (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP). 
The H-score was categorized into three groups: none 
(H-score = 0), moderate (H-score = [2.5–37.5]) and 
high (H-score > 37.5). The division between the last 
two groups corresponds to the percentile 75. Categorical 
data were summarized by frequencies and percentages, 
and continuous variables by their mean (± standard 
deviation). The associations between the explanatory 
factors and H-score were then assessed using univariable 
multinomial logistic regression models. The strength 
of the association was measured by the Relative Risk 
Ratio (RRR) and calculated P-values. Factors which 
were associated to the H-score at level of 20% (P-value 
< 0.20) were considered in a backward procedure to fit a 
multivariable model. These factors were used as adjusting 
variables to assess the association of the H-score with 
OS. For this last analysis, a Cox proportional-hazards 
regression was performed.
Abbreviations
H&E: hematoxylin and eosin; IHC: 
immunohistochemistry; mAb(s): monoclonal antibody(ies); 
OS: overall survival; RRR: relative risk ratio; TC: tumor 
cells; TIMC: tumor infiltrating mononuclear cells.
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